Boston and Guidant merger gets shareholders' OK despite Xience setback
This article was originally published in Clinica
Stockholders of Boston Scientific and Guidant have given the thumbs up to the companies' proposed merger, leaving US and EU regulatory approvals the only obstacles to the completion of the $27bn deal.
You may also be interested in...
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.
The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.